Tofacitinib-d3 (citrate)

Tofacitinib-d3 (citrate) is deuterium labeled Tofacitinib (citrate) . Tofacitinib citrate is an orally available JAK1/2/3 inhibitor with IC50s of 1, 20, and 112 nM, respectively. Tofacitinib citrate has antibacterial, antifungal and antiviral activities.

Product Specifications

CAS Number

[2701680-77-3]

Product Name Alternative

Tasocitinib-d3 (citrate) ; CP-690550-d3 (citrate)

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Apoptosis; Bacterial; Fungal; Influenza Virus; Isotope-Labeled Compounds; JAK

Type

Isotope-Labeled Compounds

Related Pathways

Anti-infection; Apoptosis; Epigenetics; JAK/STAT Signaling; Others; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt

Applications

COVID-19-anti-virus

Field of Research

Cancer; Infection; Inflammation/Immunology

Purity

99.59

Solubility

10 mM in DMSO|DMSO : 28.57mg/mL (ultrasonic) |H2O : 3.33mg/mL (ultrasonic)

Smiles

O=C(CC#N)N1C[C@H](N(C2=C3C(NC=C3)=NC=N2)C([2H])([2H])[2H])[C@H](C)CC1.O=C(CC(C(O)=O)(O)CC(O)=O)O

Molecular Formula

C22H25D3N6O8

Molecular Weight

507.51

Precautions

H302, H315, H319, H335

References & Citations

[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216.|[2]Jiang JK, et al. Examining the chirality, conformation and selective kinase inhibition of 3- ((3R,4R) -4-methyl-3- (methyl (7H-pyrrolo[2,3-d]pyrimidin-4-yl) amino) piperidin-1-yl) -3-oxopropanenitrile (CP-690,550) . J Med Chem. 2008 Dec 25;51 (24) :8012-8.|[3]LaBranche TP, et al. JAK inhibition with tofacitinib suppresses arthritic joint structural damage through decreased RANKL production. Arthritis Rheum. 2012 Nov;64 (11) :3531-42.|[4]Onda M, et al. Tofacitinib suppresses antibody responses to protein therapeutics in murine hosts. J Immunol. 2014 Jul 1;193 (1) :48-55.|[5]Yagi K, et al. Pharmacological inhibition of JAK3 enhances the antitumor activity of STI571 in human chronic myeloid leukemia. Eur J Pharmacol. 2018 Apr 15;825:28-33.